Bispecific T-Cell Engager (BiTCE)

About Ymmunobio

Ymmunobio AG is a private, preclinical-stage biotech focused on a novel, pan-tumor target, NPTXR, aiming to develop targeted therapies with high tumor specificity and low off-target toxicity. The company employs a staged development strategy, prioritizing radiopharmaceuticals and BiTCEs for rapid IND filings and early human proof-of-concept, while advancing a dual-payload ADC as its flagship asset with clinical proof-of-concept targeted for 2028. With foundational IP protection until 2044 and a leadership team experienced in drug development, Ymmunobio is positioning itself to address a broad solid tumor market, though it faces significant risks typical of early-stage biotechs, including clinical, financial, and competitive challenges.

Therapeutic Areas

Other NPTXR+ Solid Tumors Drugs